|Bid||118.00 x 600|
|Ask||122.00 x 500|
|Day's Range||118.17 - 119.17|
|52 Week Range||96.52 - 192.94|
|PE Ratio (TTM)||-11.89|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TESARO, Inc. Here are 5 ETFs with the largest exposure to TSRO-US. Comparing the performance and risk of TESARO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $1.56 billion over the last one-month.